
LOG Pharma To Showcase Barrier Eco Packaging Powered By DOW HEALTH+ Polymers At CPHI Frankfurt 2025
LOG's sustainable barrier line combines performance and cost efficiency for protection against moisture and oxygen
FRANKFURT, Germany, Oct. 6, 2025 /PRNewswire/ -- LOG Pharma Primary Packaging is joining forces with Dow , one of the world's leading materials science companies, to present LOG's innovative barrier eco line at CPHI Frankfurt 2025 , taking place on October 28–30.
The barrier eco line, which will be displayed together with LOG's other packaging solutions at Stand 8.0D74, Zone Packaging, combines sustainability, performance and cost efficiency.
By applying Dow's advanced pharma-grade HEALTH+ HDPE resins, LOG has created bottles that offer excellent protection against gas, moisture and oxygen. This means formulations stay stable and safe, without using more material than needed.
These bottles are 30% lighter while still delivering superior moisture barrier performance, twice as effective as standard HDPE containers. The product has friendlier carbon footprint, while cutting production and shipping costs.
In today's pharmaceutical landscape, protecting sensitive drug formulations is non-negotiable. Oxygen or moisture ingress can degrade active ingredients, harming efficacy and shelf life. LOG's solution offers strong barrier performance with less material.
The global barrier resins market is projected to grow from 12.4$ billion in 2021 to 16.6$ billion by 2026, with Dow as one of the key players.
"Collaborating with LOG Pharma has shown what's possible when shared vision meets advanced materials science. By using our innovative pharma-grade HEALTH+ Polymers, LOG has brought to life a bottle that is 30% lighter while maintaining superior gas and moisture barrier performance," said Zshelyz Jaynelle Lee , EMEA Senior Marketing Manager at Dow. "Together, we're driving innovation that protects sensitive formulations and advances sustainable pharmaceutical packaging."
"Our mission at LOG is to make pharmaceutical packaging both sustainable and affordable. By combining our expertise with Dow's innovative resins, we can deliver barrier solutions that truly protect sensitive medicines while supporting our customers' environmental goals," said Noam Nahari , VP Marketing and Business Development at LOG Pharma.
About LOG Pharma Primary Packaging
LOG Pharma Primary Packaging has been serving the global pharmaceutical industry for more than 50 years, offering a wide range of standard and customized packaging solutions. The company operates a manufacturing site in Israel and one in Hungary and is part of Perlen Packaging .
For more information and to schedule a meeting at CPHI 2025, visit:
Contact
Noam Nahari
VP Marketing & Business Development
LOG Pharma Primary Packaging
+972-50-7429429
[email protected]
SOURCE LOG Pharma Primary Packaging
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- VUBE Exchange Announces Unified Account Integration Across VUBE Pro, VUBE Plus, And VUBE Max
- Fitell Corporation Launches Solana (SOL) Digital Asset Treasury With $100M Financing Facility, With Focus On Yield And On-Chain Defi Innovation
- Meanwhile, Bitcoin Life Insurer, Secures $82M To Meet Soaring Demand For Inflation-Proof Savings
- Edgen Launches Multi‐Agent Intelligence Upgrade To Unify Crypto And Equity Analysis
- The Bitcoin Way Launches Panama Discovery Trip - A Premium 3-Day Plan B Experience
- Seoul Exchange, One Of Only Two Licensed Platforms For Unlisted Securities, Will Exclusively Use Story To Settle Tokenized Rwas
Comments
No comment